Further publications

ESCAMP evaluation stage 2: Evaluation of AMP therapy as a whole system

  1. Hamre HJ, Pham VN, Kern C, Rau R, Klasen J, Schendel U, Gerlach L, Drabik A, Simon L. A 4-year non-randomized comparative phase-IV study of early rheumatoid arthritis: integrative anthroposophic medicine for patients with preference against DMARDs vs. conventional therapy including DMARDs for patients without preference. Patient Preference and Adherence 2018;12:375-97 https://doi.org/10.2147/PPA.S145221

  2. Hamre HJ, Glockmann A, Schwarz R, Riley DS, Baars EW, Kiene H, et al. Antibiotic use in children with acute respiratory or ear infections: prospective observational comparison of anthroposophic and conventional treatment under routine primary care conditions. Evid Based Complement Alternat Med 2014. https://doi.org/10.1155/2014/243801

  3. Hamre HJ, Kiene H, Ziegler R, Tröger W, Meinecke C, Schnürer C, et al. Overview of the publications from the Anthroposophic Medicine Outcomes Study (AMOS) - a whole system evaluation study. Global Adv Health Med 2014;3(1):54-70. https://doi.org/10.7453/gahmj.2013.010

  4. Baars EW, Kooreman P. A 6-year comparative economic evaluation of healthcare costs and mortality rates of Dutch patients from conventional and CAM GPs. BMJ Open 2014;4(8):e005332. https://doi.org/10.1136/bmjopen-2014-005332

  5. Hamre HJ, Kiene H, Glockmann A, Ziegler R, Kienle GS. Long-term outcomes of anthroposophic treatment for chronic disease: a four-year follow-up analysis of 1510 patients from a prospective observational study in routine outpatient settings. BMC Res Notes 2013;6(269). https://doi.org/10.1186/1756-0500-6-269

  6. Jong MC, Jong MU, Baars EW. Adverse drug reactions to anthroposophic and homeopathic solutions for injection: a systematic evaluation of German pharmacovigilance databases. Pharmacoepidemiol Drug Saf 2012;21(12):1295-301. https://doi.org/10.1002/pds.3298

  7. Baars E, Koster E, Schoorel E. Client experiences with an integrated conventional and anthroposophic approach at the "Kindertherapeuticum" in Zeist. Merkurstab 2012;65(4):335-338. https://doi.org/10.14271/DMS-19994-DE

  8. Kooreman P, Baars EW. Patients whose GP knows complementary medicine tend to have lower costs and live longer. Eur J Health Econ 2012;13(6):769-76. https://doi.org/10.1007/s10198-011-0330-2

  9. Kienle GS, Glockmann A, Grugel R, Hamre HJ, Kiene H. Klinische Forschung zur Anthroposophischen Medizin - Update eines Health Technology Assessment-Berichts und Status Quo [Clinical research on anthroposophic medicine: update of a health technology assessment report and status quo]. Forsch Komplementärmed 2011:18; 269-82. https://doi.org/10.1159/000331812

  10. Hamre HJ, Witt CM, Kienle GS, Glockmann A, Willich SN, Kiene H. Predictors of outcome after 6 and 12 months following anthroposophic therapy for adult outpatients with chronic disease: a secondary analysis from a prospective observational study. BMC Res Notes 2010;3(218). https://doi.org/10.1186/1756-0500-3-218

  11. Hamre HJ, Witt CM, Kienle GS, Glockmann A, Ziegler R, Rivoir A, et al. Anthroposophic therapy for migraine: a two-year prospective cohort study in routine outpatient settings. Open Neurol J 2010;4:100-10. https://doi.org/10.2174/1874205X01004010100

  12. Hamre HJ, Witt CM, Kienle GS, Meinecke C, Glockmann A, Ziegler R, et al. Anthroposophic therapy for attention deficit hyperactivity: a two-year prospective study in outpatients. Int J Gen Med 2010;3:239-53. https://doi.org/10.2147/IJGM.S11725

  13. Hamre HJ, Witt CM, Glockmann A, Ziegler R, Kienle GS, Willich SN, et al. Health costs in patients treated for depression, in patients with depressive symptoms treated for another chronic disorder, and in non-depressed patients: a two-year prospective cohort study in anthroposophic outpatient settings. Eur J Health Econ 2010;11(1):77-94. https://doi.org/10.1007/s10198-009-0203-0